[SCHEDULE 13G] Tango Therapeutics, Inc. Passive Investment Disclosure (>5%)

Tango Therapeutics Inc: This Schedule 13G shows FMR LLC (and Abigail P. Johnson as reported) beneficially owns 9,905,919 shares of Tango Therapeutics common stock, representing 6.9% of the class.

Rhea-AI Filing Summary

Tango Therapeutics Inc: This Schedule 13G shows FMR LLC (and Abigail P. Johnson as reported) beneficially owns 9,905,919 shares of Tango Therapeutics common stock, representing 6.9% of the class. The filing lists the issuer CUSIP 87583X109 and the issuer address in Boston. The filing states voting/dispositive power figures for FMR LLC and refers to Exhibit 99 and a power of attorney incorporated by reference.

Insights

Institutional Ownership Analyst

Fidelity-affiliated ownership disclosed: 9.9M shares (6.9%).

The filing reports 9,905,919 shares beneficially owned by FMR LLC, with sole dispositive power equal to that share count. This is a passive beneficial‑ownership disclosure under Schedule 13G rather than an active Schedule 13D.

Implications depend on portfolio management decisions; the filing references an exhibit for subsidiary identification and a power of attorney incorporated by reference. Subsequent filings could clarify any changes.

Corporate Governance Specialist

Passive investor position disclosed, no control claim asserted.

The statement indicates ownership on behalf of others and notes no single other person holds more than 5% of the class. The filing follows Schedule 13G mechanics for institutional investors and includes Exhibit 99 for related agreements.

Relevant items to watch in future filings: any shift to Schedule 13D or updates to percent ownership.

Key Figures

Shares beneficially owned: 9,905,919 shares Percent of class: 6.9% CUSIP: 87583X109 +1 more

4 metrics

Shares beneficially owned 9,905,919 shares Amount beneficially owned reported on Schedule 13G

Percent of class 6.9% Percent of common stock represented by the reported shares

CUSIP 87583X109 Identifier for Tango Therapeutics common stock

Sole voting power (FMR) 9,900,706 shares Sole voting power reported on cover information

Key Terms

Schedule 13G, Beneficially owned, Dispositive power, 13d-1(k)(1)

4 terms

Schedule 13G regulatory

"This Schedule 13G shows FMR LLC beneficially owns 9,905,919 shares"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Amount beneficially owned: 9905919.00 (b) Percent of class: 6.9 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Dispositive power financial

"Sole Dispositive Power 9,905,919.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

13d-1(k)(1) regulatory

"Please see Exhibit 99 for 13d-1(k) (1) agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does FMR LLC report in Tango Therapeutics (TNGX)?

FMR LLC reports beneficial ownership of 9,905,919 shares, representing 6.9% of Tango Therapeutics' common stock, per the Schedule 13G filing filed on the provided excerpt.

Does the Schedule 13G indicate FMR LLC has voting power over these shares?

The filing reports FMR LLC has sole dispositive power over 9,905,919 shares and sole voting power of 9,900,706 shares as stated on the cover information in the excerpt.

Is this Schedule 13G a passive disclosure or an active acquisition?

This is a Schedule 13G institutional disclosure indicating a passive beneficial‑ownership position rather than an active Schedule 13D takeover or change‑of‑control filing, per the form type shown.

Who else is named in the filing alongside FMR LLC?

Abigail P. Johnson is named in the filing with beneficial ownership reported as 9,905,919 shares and 6.9% of the class, consistent with the FMR group disclosure in the excerpt.

What identifiers and exhibits are referenced in the filing?

The filing lists CUSIP 87583X109, the issuer address in Boston, and references Exhibit 99 for a 13d‑1(k)(1) agreement and a power of attorney incorporated by reference to Exhibit 24.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 11:40 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TANGO THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

87583X109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 9,900,706.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,905,919.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,905,919.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,905,919.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,905,919.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TANGO THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 201 BROOKLINE AVENUE,SUITE 901,BOSTON,MA,USA,02215
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 87583X109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 9905919.00
(b)	Percent of class: 6.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 9905919.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TANGO THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of TANGO THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	05/05/2026

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:	05/05/2026

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.